• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Insulet, Mayo Clinic get in on Glooko’s $35m Series C round

Insulet, Mayo Clinic get in on Glooko’s $35m Series C round

June 27, 2017 By Brad Perriello

Insulet (NSDQ:PODD) and Mayo Clinic were among the new investors to get in on a $35 million Series C round for Glooko and its diabetes management platform.

The round was led by new investor Georgian Partners, joined by Insulet and Mayo Clinic and existing backers Medtronic, Samsung, Canaan Partners and Social Capital, Mountain View, Calif.-based Glooko said. The proceeds are earmarked for expanding the company’s sales, marketing and development teams; boosting its commercial footprint in France, Germany, the U.K., Asia and the Middle East; and data analytics and AI development projects.

Glooko’s platform is designed to integrate data from blood glucose monitors and other devices with either an Apple (NSDQ:AAPL) iPhone or Google (NSDQ:GOOG) Android application. Food intake, medication and insulin dosage can also be recorded to provide context for changes in blood glucose readings. Data from meters and devices is sent to Glooko’s cloud-based Population Tracker, where patients and providers alike can view and analyze the data, and make decisions about interventions and treatments.

“This additional funding will help us to further our mission: to improve the lives of people with diabetes,” CEO Rick Altinger said in prepared remarks. “With this capital, we will accelerate our investments in clinical solutions that aim to increase medication adherence, provide personalized insights and prompts that drive behavior change for people with diabetes, and deliver clinical decision support to thousands of clinicians and coaches so they can better support people with diabetes in between office visits.”

“Glooko has demonstrated great traction and growth. Its scalable, device-agnostic platform not only meets the needs of people with diabetes, it also benefits health insurance plans, employers, pharma and health systems that want to effectively manage large populations of people with diabetes,” added Georgian Partners managing director Simon Chong. “We are excited to become a part of the Glooko investment team, working with Glooko on its analytics-driven approach to delivering both personal and clinical support to the diabetes community.”

Glooko, which raised a $17 million Series B round in March 2015, merged with Diasend in September 2016. Insulet and Glooko are not newfound friends; in January last year Insulet launched a Glooko-linked data management system for its OmniPod insulin management device.

Filed Under: Diabetes, Funding Roundup, Wall Street Beat Tagged With: Glooko, Insulet, Medtronic

More recent news

  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy